1 4 Atun Insead Vf 4 10 09
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,171
On Slideshare
1,089
From Embeds
82
Number of Embeds
4

Actions

Shares
Downloads
3
Comments
0
Likes
0

Embeds 82

http://blog.inseadhealthalumni.net 34
http://inseadhealthalumni.net 24
http://www.inseadhealthalumni.net 15
http://staging.gtoeurope.com 9

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The Global Fund: A Public-private Partnership to Fight Deadly Diseases Professor Rifat Atun Director, Strategy, Performance and Evaluation Cluster
  • 2. Presentation Structure • Global Health Public Private Partnerships • Segmentation • The Global Fund
  • 3. Total annual resources available for AIDS: 1986-2008 13 13 12 11 10 10 9 8297 Signing 2001 UN 8 US$ Billion Declaration of Commitment 7 on HIV/AIDS (UNGASS ) 6 5 World Bank 4 MAP launch UNAIDS PEPFAR 3 Less than US$ 1 million 2 1623 Global Fund 212 257 292 1 59 0 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Notes: [1] 1986-2000 figures are for international funds only [2] Domestic funds are included from 2001 onwards
  • 4. Global Health Partnerships Almost 100 in number • New actors in the global health landscape – Country governments (donors and recipients), philanthropy (e.g. Gates), Private Sector, Pharma, Med Tech and Civil Society • New global governance mechanisms – Transcend traditional multilateral institutions
  • 5. Investment in GHPPP (received) by 2007 Foundations – Multilateral Agencies - Private Governments 12000 10000 8000 6000 4000 US$ Millions 2000 250 200 150 100 50 0 ip ip ce sh S TM l er H sh P i I er I TH ta I V D I A R M D V tn V A R V tn W an A M N D To IP A N ar D R M ID FA H A a rIO FI TB T M lli G P P D E C P A G A P B TB -T R p D to M S ll y Li
  • 6. • Global Health Public Private Partnerships • Segmentation • The Global Fund
  • 7. Segmenting Global Health PPPs (1)
  • 8. Segmenting Global Health PPPs (2)
  • 9. Push Mechanisms: Product Development Partnerships • Global Alliance for TB Drug Development (TB Alliance) • International AIDS Vaccine Initiative (IAVI) • International Partnership for Microbicides (IPM) • Malaria Vaccine Initiative (MVI) • Medicines for Malaria Venture (MMV) • Microbicide Development Programme (MDP)
  • 10. Number of GHPPP along the R&D value chain
  • 11. Number of GHPPPs along the R&D value chain by disease area
  • 12. Push Mechanisms: Product Access Partnerships • Global Alliance for the Elimination of Lymphatic Filariasis • Global Polio Eradication Initiative (GPEI) • International Trachoma Initiative (ITI) • Malarone Donation Program • Mectizan Donation Program • WHO/Novartis Coartem® (Coartem)
  • 13. Pull Mechanisms: Global Financing Institutions • The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund) • Global Alliance for Vaccines and Immunization (GAVI Alliance)
  • 14. • Global Health Public Private Partnerships • Segmentation • The Global Fund
  • 15. Scaling up in investment By September 2009 Proportion of External Global Investment (2008) • Total pledges $21.2 Bn • 23% of HIV • Approved ~ $16.2 Bn • 60% of TB • Disbursed ~ $8.6 Bn • 75% of Malaria (142 countries and ~ 600 grants)
  • 16. Accelerating Scale Up 5.0 75 70 4.5 DOTS 65 ARV 4.0 60 ITNs ARV and DOTS (millions) 55 3.5 50 3.0 45 ITN (millions) 40 2.5 35 2.0 30 25 1.5 20 1.0 15 10 0.5 5 0.0 - 2004 2005 2006 2007 2008
  • 17. Affordable Medicines Facility – malaria Multiple eligible Co-payment ACT manufacturers First line Private NGO Buyers Public Buyers buyers Buyers (e.g. PSI, MSF) (e.g. Ministry of (e.g. National Health) Wholesalers) Wholesalers Distributors Central medical stores Medicines Money Retailers, private clinics and public providers Patients